It has been reported that it was highly expressed in small bowel neuroendocrine tumors and pancreatic neuroendocrine tumors and can predict primary tumors according to the expression of OPRK1 in metastatic tumors, which is expected to become a new promising therapeutic target [37, 38]. This evidence concerns the gene OPRK1 and pancreatic neuroendocrine tumor.